Q3 EPS Estimate for Jasper Therapeutics Lowered by Analyst

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for Jasper Therapeutics in a research report issued to clients and investors on Thursday, August 14th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($1.48) for the quarter, down from their prior forecast of ($1.31). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.96) EPS, FY2026 earnings at ($6.58) EPS, FY2027 earnings at ($7.92) EPS, FY2028 earnings at ($9.10) EPS and FY2029 earnings at ($10.14) EPS.

A number of other analysts have also recently weighed in on JSPR. William Blair restated a “market perform” rating on shares of Jasper Therapeutics in a research note on Monday, July 7th. Cantor Fitzgerald cut Jasper Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, July 7th. Evercore ISI cut their target price on Jasper Therapeutics from $50.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Royal Bank Of Canada cut Jasper Therapeutics from an “outperform” rating to a “sector perform” rating and set a $5.00 target price on the stock. in a research report on Tuesday, July 8th. Finally, Oppenheimer cut their target price on Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a research report on Thursday, May 15th. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.75.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock opened at $2.85 on Monday. Jasper Therapeutics has a 1-year low of $2.27 and a 1-year high of $26.05. The stock has a market cap of $42.81 million, a PE ratio of -0.47 and a beta of 2.70. The stock’s fifty day moving average is $4.04 and its two-hundred day moving average is $4.73.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.54).

Hedge Funds Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after buying an additional 3,828 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Jasper Therapeutics during the first quarter worth about $46,000. Tema Etfs LLC purchased a new position in shares of Jasper Therapeutics during the fourth quarter worth about $266,000. Marex Group plc purchased a new position in shares of Jasper Therapeutics during the second quarter worth about $74,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Jasper Therapeutics during the second quarter worth about $78,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.